Clemens R. Scherzer

Clemens R. Scherzer

Auto-generated profile, based on publicly available information

Clemens R. Scherzer

Stephen & Denise Adams Center for Parkinson’s Disease Research of Yale School of Medicine, New Haven, CT 06510

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2010 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BZBin Zheng
Bin Zheng
ZLZhixiang Liao
Zhixiang Liao
JLJoseph J. Locascio
Joseph J. Locascio
KLKristen A. Lesniak
Kristen A. Lesniak
SRSarah S. Roderick
Sarah S. Roderick
TCthe Global PD Gene Expression (GPEX) Consortium
the Global PD Gene Expression (GPEX) Consortium
Parkinson’s disease affects 5 million people worldwide, but the molecular mechanisms underlying its pathogenesis are still unclear. Here, we report a genome-wide meta-analysis of gene sets (groups of genes that encode the same biological pathway or process) in 410 samples from patients with symptomatic Parkinson’s and subclinical disease and healthy controls. We analyzed 6.8 million raw data points from nine genome-wide expression studies, and 185 laser-captured human dopaminergic neuron and substantia nigra transcriptomes, followed by two-stage replication on three platforms. We found 10 gene sets with previously unknown associations with Parkinson’s disease. These gene sets pinpoint defects in mitochondrial electron transport, glucose utilization, and glucose sensing and reveal that they occur early in disease pathogenesis. Genes controlling cellular bioenergetics that are expressed in response to peroxisome proliferator–activated receptor γ coactivator-1α (PGC-1α) are underexpressed in Parkinson’s disease patients. Activation of PGC-1α results in increased expression of nuclear-encoded subunits of the mitochondrial respiratory chain and blocks the dopaminergic neuron loss induced by mutant α-synuclein or the pesticide rotenone in cellular disease models. Our systems biology analysis of Parkinson’s disease identifies PGC-1α as a potential therapeutic target for early intervention.

26 July 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MLMarta M. Lipinski
Marta M. Lipinski
BZBin Zheng
Bin Zheng
TLTao Lu
Tao Lu
ZYZhenyu Yan
Zhenyu Yan
BPBenedicte Py
Benedicte Py
JYJunying Yuan
Junying Yuan
Dysregulation of autophagy, a cellular catabolic mechanism essential for degradation of misfolded proteins, has been implicated in multiple neurodegenerative diseases. However, the mechanisms that lead to the autophagy dysfunction are still not clear. Based on the results of a genome-wide screen, we show that reactive oxygen species (ROS) serve as common mediators upstream of the activation of the type III PI3 kinase, which is critical for the initiation of autophagy. Furthermore, ROS play an essential function in the induction of the type III PI3 kinase and autophagy in response to amyloid β peptide, the main pathogenic mediator of Alzheimer's disease (AD). However, lysosomal blockage also caused by Aβ is independent of ROS. In addition, we demonstrate that autophagy is transcriptionally down-regulated during normal aging in the human brain. Strikingly, in contrast to normal aging, we observe transcriptional up-regulation of autophagy in the brains of AD patients, suggesting that there might be a compensatory regulation of autophagy. Interestingly, we show that an AD drug and an AD drug candidate have inhibitory effects on autophagy, raising the possibility that decreasing input into the lysosomal system may help to reduce cellular stress in AD. Finally, we provide a list of candidate drug targets that can be used to safely modulate levels of autophagy without causing cell death.

16 January 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CSClemens R. Scherzer
Clemens R. Scherzer
AEAron C. Eklund
Aron C. Eklund
LMLee J. Morse
Lee J. Morse
ZLZhixiang Liao
Zhixiang Liao
JLJoseph J. Locascio
Joseph J. Locascio
SGSteven R. Gullans
Steven R. Gullans
Parkinson's disease (PD) progresses relentlessly and affects five million people worldwide. Laboratory tests for PD are critically needed for developing treatments designed to slow or prevent progression of the disease. We performed a transcriptome-wide scan in 105 individuals to interrogate the molecular processes perturbed in cellular blood of patients with early-stage PD. The molecular multigene marker here identified is associated with risk of PD in 66 samples of the training set comprising healthy and disease controls [third tertile cross-validated odds ratio of 5.7 ( P for trend 0.005)]. It is further validated in 39 independent test samples [third tertile odds ratio of 5.1 ( P for trend 0.04)]. Insights into disease-linked processes detectable in peripheral blood are offered by 22 unique genes differentially expressed in patients with PD versus healthy individuals. These include the cochaperone ST13 , which stabilizes heat-shock protein 70, a modifier of α-synuclein misfolding and toxicity. ST13 messenger RNA copies are lower in patients with PD (mean ± SE 0.59 ± 0.05) than in controls (0.96 ± 0.09) ( P = 0.002) in two independent populations. Thus, gene expression signals measured in blood can facilitate the development of biomarkers for PD.

15 February 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RCRuth Chia
Ruth Chia
MSMarya S. Sabir
Marya S. Sabir
SBSara Bandres-Ciga
Sara Bandres-Ciga
SSSara Saez-Atienzar
Sara Saez-Atienzar
RRRegina H. Reynolds
Regina H. Reynolds
SSSonja Scholz
Sonja Scholz

1 September 2017 in Science
Verified
Journal Article
Closed access
PDF file
SMShuchi Mittal
Shuchi Mittal
KBKjetil Bjørnevik
Kjetil Bjørnevik
DIDoo Soon Im
Doo Soon Im
AFAdrian Flierl
Adrian Flierl
XDXianjun Dong
Xianjun Dong
CSClemens R. Scherzer
Clemens R. Scherzer
Elucidating the risk of Parkinson's disease: High expression of the α-synuclein gene ( SNCA ) is a risk factor for Parkinson's disease (PD), but certain drugs may mitigate this risk. Mittal et al. ran a small-molecule screen to identify compounds that regulate levels of SNCA expression and found that several β2-adrenoreceptor (β2AR) agonists reduced them (see the Perspective by Snyder). These compounds modulated epigenetic marks at the SNCA gene, effectively suppressing SNCA transcription. The authors looked at the pharmaceutical history of more than 4 million Norwegians over an 11-year period and found a reduced risk of PD among those that were taking one of the β2AR agonists for other medical problems. Science , this issue p. 891 ; see also p. 869

16 April 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCCarolina Cebrián
Carolina Cebrián
FZFabio A. Zucca
Fabio A. Zucca
PIETROLUIGI MAURIPIETROLUIGI MAURI
PIETROLUIGI MAURI
JSJulius A. Steinbeck
Julius A. Steinbeck
LSLorenz Studer
Lorenz Studer
DSDavid Sulzer
David Sulzer
Subsets of rodent neurons are reported to express major histocompatibility complex class I (MHC-I), but such expression has not been reported in normal adult human neurons. Here we provide evidence from immunolabel, RNA expression and mass spectrometry analysis of postmortem samples that human catecholaminergic substantia nigra and locus coeruleus neurons express MHC-I, and that this molecule is inducible in human stem cell-derived dopamine (DA) neurons. Catecholamine murine cultured neurons are more responsive to induction of MHC-I by gamma-interferon than other neuronal populations. Neuronal MHC-I is also induced by factors released from microglia activated by neuromelanin or alpha-synuclein, or high cytosolic DA and/or oxidative stress. DA neurons internalize foreign ovalbumin and display antigen derived from this protein by MHC-I, which triggers DA neuronal death in the presence of appropriate cytotoxic T cells. Thus, neuronal MHC-I can trigger antigenic response, and catecholamine neurons may be particularly susceptible to T-cell-mediated cytotoxic attack.